PharmaTher’s Ketamine Receives the US FDA’s Orphan Drug Designation for Complex Regional Pain Syndrome

 PharmaTher’s Ketamine Receives the US FDA’s Orphan Drug Designation for Complex Regional Pain Syndrome

Shots:

  • The US FDA has granted ODD to the Ketamine for the treatment of complex regional pain syndrome (CRPS) which is a rare chronic pain and inflammatory condition following an injury to a limb
  • The ODD follows the US FDA’s ODD of ketamine for the treatment of ALS, granted on Aug 04, 2021
  • Ketamine acts as a noncompetitive, NMDA channel blocker that can prevent the induction of synaptic potentiation. The company is planning to initiate a P-II study of ketamine for CRPS in 2022

Click here to­ read full press release/ article | Ref: PharmaTher | Image: PharmaTher

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post